Merit Medical Systems 株価情報 (NASDAQ: MMSI)

最新ニュース Merit Medical Systems (NASDAQ:MMSI) 株価情報

MERIT MEDICAL SYSTEMS INC

Merit Medical Systems

Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.

Analyst Ratings

MMSI

Merit Medical Systems (NASDAQ:MMSI) はこの3カ月間で11人のアナリストに分析され、ベアリッシュからブルリッシュまで多岐にわたる視点が明らかになりました。

アナリストの分析｜メリットメディカルシステムに関係する11の意見

Merit Medical Systems, Inc. - Common Stock

Merit Medical Systems Inc

<ul>
<li>The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.</li>
<li>Approval was supported by superior 12-month target lesion primary patency (70.1%) and access circuit primary patency (58.1%) in the randomized arm of the trial.</li>
</ul>
SOUTH JORDAN, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), a global leader of healthcare technology, announced today that the Wrapsody Cell-Impermeable Endoprosthesis (CIE) received regulatory approval from Health Canada. With this approval, Merit intends to begin immediate commercialization of the device throughout Canada with devices shipped from Merit's Toronto distribution center.

News

Merit Medical Systems Receives Health Canada Regulatory Approval For Wrapsody Cell-Impermeable Endoprosthesis

Biotech

General

Merit Medical Releases 12-Month Efficacy Results For Single-Arm Arteriovenous Graft Cohort Of WRAPSODY Arteriovenous Efficacy Trial

Throughout the last three months, 17 analysts have evaluated Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Merit Medical Systems, revealing an average target of $114.12, a high estimate of $128.00, and a low estimate of $100.00. Observing a downward trend, the current average is 2.51% lower than the prior average price target of $117.06. 
<img src="https://www.benzinga.com/files/images/story/2025/1745618451_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Merit Medical Systems. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jon Young &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $108.00&#x7C;$127.00 &#x7C; 
&#x7C;Jayson Bedford &#x7C;Raymond James &#x7C;Lowers &#x7C;Outperform &#x7C; $108.00&#x7C;$116.00 &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Lowers &#x7C;Outperform &#x7C; $103.00&#x7C;$111.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $100.00&#x7C;$116.00 &#x7C; 
&#x7C;David Rescott &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $110.00&#x7C;$111.00 &#x7C; 
&#x7C;Jason Bednar &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $112.00&#x7C;$116.00 &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $111.00&#x7C;$111.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $116.00&#x7C;$116.00 &#x7C; 
&#x7C;Robbie Marcus &#x7C;JP Morgan &#x7C;Announces &#x7C;Overweight &#x7C; $120.00&#x7C;- &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Lowers &#x7C;Outperform &#x7C; $111.00&#x7C;$115.00 &#x7C; 
&#x7C;Jon Young &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $127.00&#x7C;$128.00 &#x7C; 
&#x7C;Larry Biegelsen &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $117.00&#x7C;$120.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $116.00&#x7C;$122.00 &#x7C; 
&#x7C;Jason Bednar &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $116.00&#x7C;$114.00 &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Raises &#x7C;Outperform &#x7C; $115.00&#x7C;$114.00 &#x7C; 
&#x7C;Jon Young &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $128.00&#x7C;$127.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $122.00&#x7C;$109.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Merit Medical Systems. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merit Medical Systems compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Merit Medical Systems's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Merit Medical Systems's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MMSI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Merit Medical Systems analyst ratings.</a>
<h2>Discovering Merit Medical Systems: A Closer Look</h2>
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
<h3>Merit Medical Systems's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Merit Medical Systems displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 9.44%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Merit Medical Systems's net margin is impressive, surpassing industry averages. With a net margin of 7.87%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Merit Medical Systems's ROE stands out, surpassing industry averages. With an impressive ROE of 2.07%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.17%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.58, Merit Medical Systems adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Merit Medical Systems In The Eyes Of 17 Experts

Canaccord Genuity analyst Jon Young maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and lowers the price target from $127 to $108.

Price Target

Canaccord Genuity Maintains Buy on Merit Medical Systems, Lowers Price Target to $108

Raymond James analyst Jayson Bedford maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Outperform and lowers the price target from $116 to $108.

Raymond James Maintains Outperform on Merit Medical Systems, Lowers Price Target to $108

Barrington Research analyst Michael Petusky maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Outperform and lowers the price target from $111 to $103.

Barrington Research Maintains Outperform on Merit Medical Systems, Lowers Price Target to $103

Needham analyst Mike Matson maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and lowers the price target from $116 to $100.

Needham Maintains Buy on Merit Medical Systems, Lowers Price Target to $100

Baird analyst David Rescott maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Outperform and lowers the price target from $111 to $110.

Baird Maintains Outperform on Merit Medical Systems, Lowers Price Target to $110

WIIM

MMSI stock has given up its prior loss. Merit Medical Systems shares were trading lower after the company cut its FY25 adjusted EPS guidance.

Merit Medical Systems shares are trading lower after the company cut its FY25 adjusted EPS guidance.

Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) lowers FY2025 Adj EPS guidance from $3.58-$3.70 to $3.29-$3.42 vs $3.65 analyst estimate. Affirms FY2025 sales outlook from $1.47 billion-$1.49 billion to $1.47 billion-$1.49 billion vs $1.48 billion estimate.

Guidance

Merit Medical Systems Lowers FY2025 Adj EPS Guidance from $3.58-$3.70 to $3.29-$3.42 vs $3.65 Est; Affirms FY2025 Sales Guidance of $1.47B-$1.49B vs $1.48B Est

Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.75 by 14.67 percent. This is a 11.69 percent increase over earnings of $0.77 per share from the same period last year. The company reported quarterly sales of $355.35 million which beat the analyst consensus estimate of $352.57 million by 0.79 percent. This is a 9.84 percent increase over sales of $323.51 million the same period last year.

Earnings

Earnings Beats

Merit Medical Systems Q1 Adj. EPS $0.86 Beats $0.75 Estimate, Sales $355.35M Beat $352.57M Estimate

ADXN

ALEX

ALLE

AMAL

AMBP

APOG

APPF

BAFN

BCPC

BELFA

BELFB

BFST

BHLB

BWMX

CBRE

CIVB

CMCSA

CNOB

COUR

CUBI

CURB

DAIO

DGICA

DGICB

ERIE

FARO

FBIZ

FCFS

FCNCA

FFBC

FRME

GBCI

GILD

GLPI

GNFT

GOOG

GOOGL

HELE

HFWA

IBCP

INDV

INTC

ITGR

KNSL

KRNY

LADR

LYTS

MBLY

MGRC

MOFG

Earnings Scheduled For April 24, 2025

Piper Sandler analyst Jason Bednar maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Overweight and lowers the price target from $116 to $112.

Piper Sandler Maintains Overweight on Merit Medical Systems, Lowers Price Target to $112

Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) has outperformed the market over the past 20 years by 2.48% on an annualized basis producing an average annual return of 10.32%. Currently, Merit Medical Systems has a market capitalization of $5.38 billion. 
Buying $1000 In MMSI: If an investor had bought $1000 of MMSI stock 20 years ago, it would be worth $7,043.75 today based on a price of $91.00 for MMSI at the time of writing.
<h3>Merit Medical Systems's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745337626_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Merit Medical Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) is <a href="https://www.benzinga.com/pressreleases/25/04/g44675330/merit-medical-systems-to-announce-first-quarter-2025-results-on-april-24-2025" target="_blank" rel="noreferrer noopener">scheduled to release</a> its first quarter 2025 adjusted EPS of 75 cents and sales of $352.82 million, as per <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">data on Benzinga Pro</a>.
Merit develops, manufactures and distributes proprietary medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy.
Barrington Research writes that in 2024, about 41% of Merit Medical&#8217;s revenue of $1.36 billion was generated outside of the U.S., and about 11% of Merit Medical&#8217;s 2024 revenue <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43956487/merit-medical-reports-fourth-quarter-and-full-year-2024-results-and-issues-fiscal-year-2025-guidan" rel="noreferrer noopener">was generated in China</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/44763932/stellantis-q1-shipments-decline-9-but-gains-in-south-america-and-eu-offer-relief" rel="noreferrer noopener">Stellantis Q1 Shipments Decline 9%, but Gains in South America and EU Offer Relief</a>
Analyst Michael Petusky also highlights the company&#8217;s several manufacturing and packaging facilities outside of the U.S., including in Mexico, Brazil, Ireland, France, The Netherlands and Singapore — along with U.S.-based manufacturing and packaging in Utah, Texas, Virginia and Minnesota.
Petusky believes most of the products Merit makes in Mexico — its most important international facility — are protected by the USMCA trade agreement, which is still in effect. Thus, the company is shielded from recent U.S. <a href="https://www.benzinga.com/topic/tariffs">tariffs on Mexican goods</a>.
The analyst maintains the outperform rating and <a target="_blank" href="https://www.benzinga.com/quote/MMSI/analyst-ratings" rel="noreferrer noopener">price target of $111</a>.
But the growing trade tensions between the U.S. and China pose a serious risk to Merit&#8217;s $150 million revenue from China.
While it seems unlikely that tariffs over 100% will last long between the world&#8217;s two biggest economies, if they do, it would significantly affect Merit&#8217;s financial outlook for the rest of 2025 and beyond, including its long-term growth plans.
Merit Medical forecasts fiscal year 2025 revenue of $1.47 billion-$1.49 billion versus a consensus of $1.477 billion. The company estimates Adjusted EPS of $3.58-$3.70 versus the consensus of $3.74.
Continued Growth Initiatives covers the 2024-2026 timeframe, and key goals include 5%-7% annual organic revenue growth, $400 million in aggregate free cash flow, and a minimum of 200 bps points of adjusted operating margin improvement to at least 20% by the end of the long-range plan.
MMSI Price Action: Merit Medical Systems stock is up 0.16% at $91.69 at publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44762037/morgan-stanleys-q1-equity-revenue-jumps-45-buoyed-by-asian-clients-amid-volatile-trading-environment" target="_blank" rel="noreferrer noopener">Morgan Stanley Q1 Credit Loss Provision Jumps To $135 Million On &#8216;Weakening Macroeconomic Forecast,&#8217; Equity Revenue Jumps 45%</a></li>
</ul>
Photo: New Africa via Shutterstock

Analyst Color

Health Care

Previews

US-China Trade Tensions Pose Risk To Merit Medical's $150 Million Revenue From China

Barrington Research analyst Michael Petusky maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Outperform and maintains $111 price target.

Barrington Research Maintains Outperform on Merit Medical Systems, Maintains $111 Price Target

Needham analyst Mike Matson reiterates Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and maintains $116 price target.

Reiteration

Needham Reiterates Buy on Merit Medical Systems, Maintains $116 Price Target

Merit Medical Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NYSE">MMSI</a>) short percent of float has risen 7.66% since its last report. The company recently reported that it has 3.24 million shares sold short, which is 8.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.63 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Merit Medical Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743601521_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Merit Medical Systems has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Merit Medical Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Merit Medical Systems's peer group average for short interest as a percentage of float is 7.78%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Merit Medical Systems?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keefe, Bruyette &amp; Woods analyst Ryan Tomasello initiated coverage on Zillow Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) with a Market Perform rating and announced a price target of $80. Zillow shares closed at $70.35 on Thursday. <a href="https://www.benzinga.com/quote/Z/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Andrew Cooper initiated coverage on UFP Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFPT#NASDAQ">UFPT</a>) with a Market Perform rating. UFP Technologies shares closed at $110.09 on Thursday. <a href="https://www.benzinga.com/quote/UFPI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Andrew Cooper initiated coverage on Integer Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITGR#NYSE">ITGR</a>) with an Outperform rating and announced a price target of $145. Integer shares closed at $117.50 on Thursday. <a href="https://www.benzinga.com/quote/ITGR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Robbie Marcus initiated coverage on Merit Medical Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with an Overweight rating and announced a price target of $120. Merit Medical shares closed at $103.27 on Thursday. <a href="https://www.benzinga.com/quote/MMSI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Michael Goldsmith initiated coverage on Getty Realty Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTY#NYSE">GTY</a>) with a Neutral rating and announced a price target of $32. Getty Realty shares closed at $30.57 on Thursday. &nbsp;<a href="https://www.benzinga.com/quote/GTY/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MMSI stock? Here&#8217;s what analysts think: 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock">Jim Cramer: Stryker Is A &#8216;Good&#8217; Company, Says He Likes This Utilities Stock</a></li>
</ul>
Photo: Shutterstock

Initiation

Pre-Market Outlook

Markets

UFPT

This Merit Medical Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Press Releases

Merit Medical Reports Fourth Quarter and Full Year 2024 Results and Issues Fiscal Year 2025 Guidance

First Patient Enrolled in Merit Medical's PREEMIE Study

Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership

Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)

Updated ASGE Clinical Practice Guideline Includes TIF 2.0 and cTIF for Management of GERD

Merit Medical Systems to Announce First Quarter 2025 Results on April 24, 2025

Merit Medical Launches the Ventrax™ Delivery System

Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial

Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis

Align Technology

Avanos Medical

Bioventus

Cerus

The Cooper Companies, Inc. - Common Stock

Cooper Companies

Cuprina Holdings (Cayman) Limited - Ordinary shares

Cuprina Holdings (Cayman)

Embecta

Establishment Labs Holdings Inc. - Common Shares

Establishment Labs Hldgs

Haemonetics

ICU Medical

OrthoPediatrics

Lantheus Holdings

Neogen

InspireMD

OraSure Technologies, Inc. - Common Stock

OraSure Technologies

Rockwell Medical

RxSight

Sanara MedTech

Solventum

Staar Surgical

UFP Technologies

Utah Medical Products, Inc. - Common Stock

Utah Medical Products

VolitionRX

Dentsply Sirona

Xtant Medical Holdings, Inc. Common Stock

Xtant Medical Hldgs

Canaccord Genuity

Raymond James

Barrington Research

Needham

Baird

Merit Medical

Merit Med Sys

Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) はこの3カ月間で11人のアナリストに分析され、ベアリッシュからブルリッシュまで多岐にわたる視点が明らかになりました。
以下の表で、アナリストによる最新のレーティングの簡潔な概要を提供し、過去30日間のセンチメントの変化について洞察し、全体像を考える上で1ヶ月前と比較しています。
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th></th>
<th style="text-align: right;">ブルリッシュ</th>
<th style="text-align: right;">ややブルリッシュ</th>
<th style="text-align: right;">無関心</th>
<th style="text-align: right;">ややベアリッシュ</th>
<th style="text-align: right;">ベアリッシュ</th>
</tr>
</thead>
<tbody>
<tr>
<td>総合レーティング</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>直近30日</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1ヶ月前</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2ヶ月前</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3ヶ月前</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
さらに、アナリストは12ヶ月の株価ターゲットを設定し、その結果、平均ターゲットが93.45ドル、最高予想が112.00ドル、最低予想が85.00ドルとなりました。現状の平均値は92.50ドルの前回の平均的な株価ターゲットから1.03％上昇しているため、株価は上昇の傾向にあると言えます。
<img decoding="async" src="https://www.benzinga.com/files/images/story/2024/1714586486_0.png" alt="price target chart" />
<h2>アナリストのレーティングを理解する：包括的な解説</h2>
最新のアナリストの行動の分析により、金融専門家がMerit Medical Systemsをどのように認識しているのかが明らかになりました。以下の概要では、主要なアナリスト、彼らの最新の評価、レーティングおよび株価ターゲットの変更について説明しています。
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>アナリスト</th>
<th>アナリスト会社</th>
<th>取った行動</th>
<th>レーティング</th>
<th>現在の株価ターゲット</th>
<th>以前の株価ターゲット</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>100.00ドル</td>
<td>98.00ドル</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>97.00ドル</td>
<td>95.00ドル</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>85.00ドル</td>
<td>88.00ドル</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>98.00ドル</td>
<td>98.00ドル</td>
</tr>
<tr>
<td>Kristen Stewart</td>
<td>CL King</td>
<td>Announces</td>
<td>Buy</td>
<td>88.00ドル</td>
<td>&#8211;</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>88.00ドル</td>
<td>&#8211;</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>87.00ドル</td>
<td>82.00ドル</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>98.00ドル</td>
<td>96.00ドル</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>88.00ドル</td>
<td>81.00ドル</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>112.00ドル</td>
<td>102.00ドル</td>
</tr>
<tr>
<td>Craig Bijou</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>87.00ドル</td>
<td>&#8211;</td>
</tr>
</tbody>
</table>
<h3>主な洞察：</h3>
<ul>
<li>取った行動：アナリストは、市場条件や企業の業績が変わった際に、その都度彼らの提案を更新しています。彼らが自社の最新の動向にどのように反応しているかは、&#8221;維持&#8221;、&#8221;引き上げ&#8221;、&#8221;引き下げ&#8221;といったキーワードが示唆しているものです。これにより、アナリストが現在の会社の状況をどのように認識しているかがわかります。</li>
<li>レーティング：アナリストは、メリットメディカルシステムについての相対的な性能についての予想を伝える、OutperformからUnderperformまでのレーティングを割り当てています。</li>
<li>株価ターゲット：アナリストはメリットメディカルシステムの将来的な価値についての見通しを提供するため、株価ターゲットを設定しています。現在と以前のターゲットを比較することで、アナリストの期待値の変化が分かります。</li>
</ul>
これらのアナリストの評価を、メリットメディカルシステムの市場ポジションについて重要な金融指標と一緒に評価することで、市場の全体像を包括的に把握することができます。レーティングテーブルを使って、最新の情報を把握し、適切な意思決定を行ってください。
アナリストの最新のレーティング情報をチェックする
<h2>メリットメディカルシステムの評価：詳細を見る</h2>
Merit Medical Systems Incは、介入的心臓血管外科、放射線学および内視鏡検査手技に使用する製品の開発・製造を行う医療機器会社です。同社の事業部門は2つあり、カーディオバスキュラーとエンドスコピーがあります。売上の大部分はカーディオバスキュラーセグメントから得られています。売上の大半は米国から得られています。
<h3>Merit Medical Systems：財務パフォーマンスの解析</h3>
時価総額のハイライト： この会社の時価総額は、業界平均を上回っているため、強固な自己資本と市場支配力を示しています。
売上高の成長： Merit Medical Systemsは、この3ヶ月間の間に好調な業績を見せています。2023年12月31日時点で、同社は売上高約10.6％の好調な成長率を達成しました。これは、同社のトップラインの収益が顕著に増加したことを示しています。他の業界大手企業と比較しても、Merit Medical Systemsの売上高成長率は、ヘルスケアセクターの業界平均を下回っていることが分かります。
純利益率： Merit Medical Systemsの財務の強さは、業界平均を上回る純利益率で示されています。同社の純利益率は8.51％で、強固な利益性と効果的なコスト管理を示しています。
自己資本利益率（ROE）： Merit Medical Systemsは、業界平均を上回る優れたROEを示しています。同社のROEは2.27%で、自己資本の効果的な利用と強固な財務健全性を示しています。
総資産利益率（ROA）： Merit Medical SystemsのROAは、業界基準を超える1.34%に達しています。これは、同社が資産を効果的に管理していることと、強固な財務健全性を示しています。
負債管理： Merit Medical Systemsの負債対自己資本比率は、業界平均を下回る0.74を記録しており、負債調達への依存度が低いことと、慎重な財政方針が起因しています。
<h2>アナリストのレーティングの要点：投資家が押さえておくべきこと</h2>
アナリストによるレーティングは、銀行業務と金融システムの分野における専門家による株式のパフォーマンスの重要な指標として機能します。これらの専門家は、企業の財務諸表を熱心に分析し、電話会議に参加し、社内者と連携して、個々の銘柄について四半期ごとのレーティングを生成しています。
一部のアナリストは、役立つ指標として、同社の収益、売上高、また成長予測について予測を提供しており、これにより投資家がどの銘柄を選択すべきかの指針を提供しています。株式およびセクターのアナリストは専門家であると同時に人間であるということを念頭に置いておくことが重要です。
本記事はBenzingaの自動コンテンツエンジンによって生成され、編集者によってレビューされました。

Comments

Merit Medical Systems

ニュース

最新ニュース Merit Medical Systems (NASDAQ:MMSI) 株価情報

水曜日, 5 01, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル